Annexon Inc logo

Annexon Inc

$ 7.46 +0.15 (+2.05%) 10:08 PM EST
P/E:
At Loss
P/B:
1.36
Market Cap:
$ 355.32M
Enterprise V:
$ 112.36M
Volume:
217.45K
Avg Vol (2M):
170.46K
Volume:
217.45K
Market Cap $:
355.32M
PE Ratio:
At Loss
Avg Vol (2-Month):
170.46K
Enterprise Value $:
112.36M
PB Ratio:
1.36

Business Description

Description
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.
Name Current Vs Industry Vs History
Cash-To-Debt 8
Equity-to-Asset 0.83
Debt-to-Equity 0.13
Debt-to-EBITDA -0.23
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -27.2
3-Year EPS without NRI Growth Rate -28.2
3-Year FCF Growth Rate -23.2

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 81.68
9-Day RSI 76.39
14-Day RSI 71.4
6-1 Month Momentum % -3.08
12-1 Month Momentum % -28.14

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 13.59
Quick Ratio 13.59
Cash Ratio 13.33

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -49.9
Name Current Vs Industry Vs History
ROE % -64.38
ROA % -52.47
ROIC % -346.48
ROC (Joel Greenblatt) % -399.94
ROCE % -56.73